Shares in Cipla rallied in a falling market, after the company said that it has received Establishment Inspection Report (EIR) from the US FDA for its Indore facility, indicating formal closure of the US FDA inspection conducted in July/August, 2015.

The shares of Cipla were up 1.2 per cent at Rs 588 on the NSE.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For over 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries.

GoodReturns.in